Home > Search Clinical Trials > Cancer - Multiple Myeloma

IRB No. U26-139-1 (Dr. Swarup Kumar, PI): A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody- TRIlogy-4

The purpose of this study is to compare the effects of the investigational drug, called JNJ-79635322, with the BCMAxCD3 bispecific antibody, called Teclistamab, after at least 3 prior lines of therapy in patients with multiple myeloma.

IRB No. U26-277-2 (Dr. Swarup Kumar, PI): A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide - TRIlogy-5

The purpose of this study is to compare the effects of the investigational drug called JNJ-79635322 against teclistamab in patients with multiple myeloma after 1 to 3 lines of prior therapy.